What’s going wrong for ASX cannabis shares lately?

Why Aussie cannabis companies are worth watching right now…
The post What’s going wrong for ASX cannabis shares lately? appeared first on The Motley Fool Australia. –

ASX cannabis shares have been smashed in the past week or so. Leading names like Little Green Pharma Ltd (ASX: LGP) and Creso Pharma Ltd (ASX: CPH) finished last week firmly in the red.

So, what’s going wrong for ASX cannabis shares lately and how have they performed?

What’s going wrong for ASX cannabis shares lately?

Interestingly, it’s not as though shares in these Aussie companies are performing poorly over the longer term. Little Green Pharma shares are up 157% in the past 12 months while the Creso Pharma share price has climbed 200% higher in the same period.

However, the past week or so has seen a correction of sorts. Mixed financial results in the August reporting season may be one factor weighing on ASX cannabis shares right now.

For instance, Little Green Pharma reported a 218% surge in revenue to $7 million in FY21 alongside some key strategic moves. The Aussie cannabis group successfully imported its first shipment of THC 16 cannabis flower medicine from Denmark to Australia, sparking a share price surge at the time.

With no major regulatory news in recent weeks, it appears that the recent earnings season has sparked a pullback from investors. The Incannex Healthcare Ltd (ASX: IHL) share price has rocketed 166.7% higher in 2021 but still edged 1.2% lower in the last 5 days.

That could indicate investors in ASX cannabis shares are cashing in some of their recent gains rather than any fundamental correction in value.

Some shares, like MGC Pharmaceuticals Ltd (ASX: MXC), have been boosted by recent announcements. MGC Pharma received approval for the UK import and prescription of its CannEpil+ product last week which sparked a share price surge.

One factor could be the risk of increased competition in the sector. Cronos Australia (ASX: CAU) and Queensland-based CDA Health entered into an $85 million merger announcement last week as it looks to increase the size and scale of its operations.

Foolish takeaway

It’s been a busy little period for ASX cannabis shares. Given the fledgling nature of the industry and the size of these Aussie companies, investors will be keeping a close eye on them in the final quarter of the year.

The post What’s going wrong for ASX cannabis shares lately? appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

Why the Little Green Pharma (ASX:LGP) share price has lost 20% since July
Creso Pharma (ASX:CPH) share price lifts following two positive updates
Creso (ASX:CPH) share price edges 4% higher following export deal
The Incannex (ASX:IHL) share price is up 40% in a month. Here’s why
MGC Pharma (ASX:MXC) share price jumps 11% on UK approval

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!